Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- (-) Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- (-) Elements of Value
- Evidence for Decision Making
- (-) Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- (-) Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 107 Results
FDA’s Real-World Data and Evidence Framework Is a Good Step Forward
The U.S. Food and Drug Administration today released its framework for evaluating the potential use of real-world evidence (RWE) to help support the approval of a new indication for a pre-approved…
Case Study Shows Benefits of Engaging Employees in Health Benefit Design
As open enrollment season for health insurance gets underway, a new case study shows that employees who are meaningfully engaged in deliberating and designing their health care benefits may have a…
Prioritizing Health Care Spending: Engaging Employees in Health Care Benefit Design
A case study shows that employees who are who are meaningfully engaged in deliberating and designing their health care benefits may have a more positive view of their coverage options.
NPC in Specialty Pharmacy Times: Inconsistent Specialty Pharmaceutical Coverage Threatens Care Coordination, Continuity
In his latest column for Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explores research published in Health Affairs that sheds light on when and how payers cover…
Get to Know Duke Margolis-NPC Postdoctoral Health Policy Fellow Taruja Karmarkar, PhD
Duke Margolis-NPC Postdoctoral Health Policy Fellow Taruja Karmarkar, PhD, sat down with us to discuss her upcoming research, bridging the gap between academia and health care stakeholders, tips for…
Real-World Data in the Current Health Care Environment
In this guest blog post, Dr. Eberechukwu Onukwugha of the University of Maryland School of Pharmacy's Department of Pharmaceutical Health Services Research explores the value of real-world data.
Study of U.S. Commercial Health Plans Shows Widespread Variation in Coverage and Reimbursement for Specialty Medicines
Research published in Health Affairs shows that insurance coverage and reimbursement for specialty medications varies substantially, finding that only 15.9% of drug coverage policies were consistent…
Financial Impact of HSA-HDHP Reform to Improve Access to Chronic Disease Management Medications
According to an issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication adherence…
NPC at ISPOR 2018: Gathering and Curating Real-World Data
The use and importance of real-world evidence (RWE) in clinical decision-making has been frequently cited by Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb, so it’s not surprising…
Managing PBMs: An Employer’s Perspective
During a webinar hosted by the Integrated Benefits Institute on March 5, Chuck Reynolds, consultant for Benfield, a Division of Gallagher Benefit Services, and Kristen Putnam, Director, Global…
A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures
Payer evaluation and coverage of pharmaceuticals and medical procedures may differ independent of their clinical benefit. Therapy access depends on factor other than cost and clinical benefit,…
Coverage Decisions May Drive Potential Health Care System Inefficiency
New research from Tufts Medical Center and the National Pharmaceutical Council indicates that patient access to therapies depends on factors other than cost and clinical benefit.
NPC in AJPB: Working Toward Better Value in Prescription Drug Benefits Management
U.S. employers provide a vital link to health care, with more than 56 percent of them offering health insurance for their employees. However, how employers design those health benefits can vary…
Toward Better Value
There is a disconnect between the important role employers believe their pharmacy benefit managers (PBMs) play in helping to manage prescription drug benefits and employers’ perceptions of the…
NPC Talks Value, Benefit Design at AMCP Research Symposium and Nexus 2017
The National Pharmaceutical Council (NPC) is pleased to be participating in next week’s Academy of Managed Care Pharmacy (AMCP) Nexus 2017 meeting in Dallas, Texas. As a sponsor of and participant in…
NPC in Chain Drug Review: Should Patients With the Same Condition Bear Different Costs?
NPC President Dan Leonard tackles variable copays in his latest commentary for Chain Drug Review. In it, he considers when variable cost-sharing is less acceptable for patients who require higher…
Checking In With Schaeffer-NPC Postdoctoral Fellow in Health Policy, Dr. Ilene Hollin
Ilene Hollin, PhD, is entering the second year of her NPC-USC Schaeffer Center Health Policy fellowship, a post-doctoral, two-year fellowship that seeks to bridge the gap between health research and…
Same Condition, Different Costs: Should Patients Pay Different Amounts?
Patients who have the same condition sometimes pay different out-of-pocket costs for their medications, but when is this differential more appropriate? Join NPC in tackling this dilemma in the…
Optimization of Medication Use at Accountable Care Organizations
This study assesses a broad range of factors related to how accountable care organizations optimize medication use and meet financial and quality metrics.